SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:5126605d-0eb0-4d58-a6e8-b6ccbe33e5dd"
 

Search: onr:"swepub:oai:lup.lub.lu.se:5126605d-0eb0-4d58-a6e8-b6ccbe33e5dd" > Inhibition of delta...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Lincoff, A. Michael (author)

Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial

  • Article/chapterEnglish2014

Publisher, publication year, extent ...

  • 2014-05-05
  • Oxford University Press (OUP),2014

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:5126605d-0eb0-4d58-a6e8-b6ccbe33e5dd
  • https://lup.lub.lu.se/record/4787351URI
  • https://doi.org/10.1093/eurheartj/ehu177DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Aims Delcasertib is a selective inhibitor of delta-protein kinase C (delta-PKC), which reduced infarct size during ischaemia/reperfusion in animal models and diminished myocardial necrosis and improved reperfusion in a pilot study during primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI). Methods and results A multicentre, double-blind trial was performed in patients presenting within 6 h and undergoing primary PCI for anterior (the primary analysis cohort, n = 1010 patients) or inferior (an exploratory cohort, capped at 166 patients) STEMI. Patients with anterior STEMI were randomized to placebo or one of three doses of delcasertib (50,150, or 450 mg/h) by intravenous infusion initiated before PCI and continued for similar to 2.5 h. There were no differences between treatment groups in the primary efficacy endpoint of infarct size measured by creatine kinase MB fraction area under the curve (AUC) (median 5156, 5043, 4419, and 5253 ng h/mL in the placebo, delcasertib 50, 150, and 450 mg/mL groups, respectively) in the anterior STEMI cohort. No treatment-related differences were seen in secondary endpoints of infarct size, electrocardiographic ST-segment recovery AUC or time to stable ST recovery, or left ventricular ejection fraction at 3 months. No differences in rates of adjudicated clinical endpoints (death, heart failure, or serious ventricular arrhythmias) were observed. Conclusions Selective inhibition of delta-PKC with intravenous infusion of delcasertib during PCI for acute STEMI in a population of patients treated according to contemporary standard of care did not reduce biomarkers of myocardial injury.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Roe, Matthew (author)
  • Aylward, Philip (author)
  • Galla, John (author)
  • Rynkiewicz, Andrzej (author)
  • Guetta, Victor (author)
  • Zelizko, Michael (author)
  • Kleiman, Neal (author)
  • White, Harvey (author)
  • McErlean, Ellen (author)
  • Erlinge, DavidLund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)kard-der (author)
  • Laine, Mika (author)
  • dos Santos Ferreira, Jorge Manuel (author)
  • Goodman, Shaun (author)
  • Mehta, Shamir (author)
  • Atar, Dan (author)
  • Suryapranata, Harry (author)
  • Jensen, Svend Eggert (author)
  • Forster, Tamas (author)
  • Fernandez-Ortiz, Antonio (author)
  • Schoors, Danny (author)
  • Radke, Peter (author)
  • Belli, Guido (author)
  • Brennan, Danielle (author)
  • Bell, Gregory (author)
  • Krucoff, Mitchell (author)
  • KardiologiSektion II (creator_code:org_t)

Related titles

  • In:European Heart Journal: Oxford University Press (OUP)35:37, s. 2516-25231522-96450195-668X

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view